INTRODUCTION
Hepatitis C virus (HCV) affects ~200 million people worldwide. HCV infection is considered to be one of the major risk factors for liver-related pathogenesis. The World Health Organization (WHO) suggests that more than 71 million peopleare chronically infected with HCV globally, and approximately 0.4 million infected people dieddue to HCV-related liver complications annually [1] [2] [3] . Chronic hepatitis C (CHC) is characterised by a highly variable progression anddepending on the extent of liver fibrosis and inflammation -CHC can progress to cirrhosis and hepatocellular carcinoma (HCC) [4, 5] . Early treatment to prevent cirrhosis is the preferred strategy to avoid HCC development. Proper management including monitoring of fibrosis progression and the use of effective antiviral therapies (e.g direct-acting antivirals-DAAs), have dramatically changed the outcome in patients with chronic HCV infection, and thereby improving liver histology, and preventing the progression to liver cirrhosis [6] .
Non-invasive approaches instead of liver biopsies are needed to determine fibrosis stage to improve prophylaxis and clinical management of patients with CHC. Until recently, a liver biopsy was the "gold standard" for assessing liver fibrosis. It had a number of limitations, such as invasive sampling error [7] [8] [9] and large variability between observers [10] . To overcome these limitations, non-invasive diagnostic methods are now increasingly used to assess liver tissue including methods based on panels of serum biomarkers [11, 12] or the measurement of liver stiffness by ultrasound (US) and magnetic resonance (MR) elastography techniques [13, 14] . Functional imaging techniques, including MR elastography and US elastography are useful for assessing moderate to advanced liver fibrosis. MR elastography is considered the most accurate noninvasive imaging technique, and US elastography is currently the most widely used noninvasive means. However, these modalities are less accurate in early-stage liver fibrosis and some factors affect the accuracy of these techniques [15] .
In addition, most of the available non-invasive models are less accurate at detecting intermediate fibrosis stages (i.e. F1-F2 on the METAVIR scale) copared to late stage cirrhosis (F4) [16] [17] [18] . Indeed, while various serum-based predictive models (such as the APRI index, the FIB-4 score, and the Forns index) for liver fibrosis have been proposed and validated [10] [11] [12] [13] [14] , their diagnostic accuracy remains hotly debated [19, 20] . Therefore, we require more accurate non-invasive models to predict the evolution of liver fibrosis in order to precisely manage it in personalized clinical medicine.
One of the serum biomarkers that has been investigated for its role in assessing liver fibrosis is pentraxin 3 (PTX3) [21] . Under normal conditions, blood levels of PTX3 are quite low (<2 ng/mL), but its expression increases in response to inflammatory stimulation in many diseases, including hepatitis [22] . Specifically, in patients with non-alcoholic fatty liver disease and alcoholic hepatitis, PTX3 levels were shown to be associated disease progression and liver fibrosis stage [23] [24] [25] . Similarly, we previously demonstrated that PTX3 levels were associated with histological fibrosis stage values, and that PTX3 serum concentrations showed high reliability for the diagnosis of significant fibrosis in patients with CHC before antiviral treatment [26] .
Obtained results allowed us to hypothesize that, incorporating PTX3 serum concentrations into a multidimensional model may be beneficial for predicting fibrosis stage in patients with CHC. Here we present (and validate) a novel predictive model (named the Pentra score) for evaluating significant fibrosis (i.e. F2 or more on the METAVIR scale) in CHC patients using PTX3 levels and other serum-based biomarkers. We show the Pentra score has comparable diagnostic performance to existing indices, with some added advantages.
PATIENTS AND METHODS

Study population
A total of 242 patients with chronic hepatitis C admitted to the Department of Infectious Diseases and Hepatology of the Wroclaw Medical University from October 2015 to April 2018, who underwent liver biopsy and for whom stored sera were available, were included.
Patients were diagnosed with CHC infection based on the following: persistently elevated alanine aminotransferase (ALT) levels; anti-HCV and HCV-RNA positivity for at least 6 months; and histopathologic features indicative of liver inflammation. CHC was confirmed by measuring serum levels of HCV antibodies via an enzyme immunoassay and HCV-RNA by RT PCR (Cobas Amplicor Roche). The patients in this study had not previously undergone antiviral therapy.
Patients' characteristics
In total, 242 participant were included in the study: 135 (55.79%) were male and 107 (44.21%) were female. The study group showed widespread intensification of liver fibrosis in the entire distribution of the METAVIR stage. Overall, 21.07% of patients were classified as stage 0 (no fibrosis) and 22.31% as stage 1 (fibrosis restricted to the portal tract). The prevalence of significant fibrosis was 56.61%: 21.07% as stage 2 (few septa extending beyond the portal tract but with intact architecture) and 35.54% as stages 3 or 4 (bridging fibrosis or cirrhosis, respectively). A training set (n = 150) was used to investigate the variables linked to the presence of significant fibrosis in patients with CHC using univariate and multivariate analyses, and then to construct a predictive model. The reproducibility of the model was then tested in a validation set (n = 92). The purpose of each examination was fully explained, and informed consent was obtained from all participants. 
Liver histology and quantification of liver fibrosis
Liver biopsies were obtained under ultrasound guidance. Specimens were fixed with formalin, paraffin-embedded, and then stained with hematoxylin and eosin. An expert pathologist blinded to patients' clinical characteristics scored the specimens according to the METAVIR scoring system, including the fibrosis score (F0, no fibrosis; F1, portal fibrosis alone; F2, portal fibrosis with rare septa; F3, portal fibrosis with many septa; and F4, cirrhosis) and the necroinflammatory activity score (A1, mild activity; A2, moderate activity; and A3, marked activity). In this study, we defined 'significant fibrosis' as a score of F2 or more. All patients with a score of F4 had compensated disease. There were no deaths associated with the liver biopsies.
Other models for staging of liver fibrosis
Other prediction models used to assess liver fibrosis in this study were the AST to Platelet Ratio Index (APRI) [27] , the Fibrosis-4 (FIB-4) score [28] , and the Forns index [16] , as 
Statistical analysis
Data analysis was carried out using Statistica 13.3 (StatSoft, Krakow, Poland). Continuous variables were expressed as median (Q25-Q75) and compared using the Mann-Whitney U test; categorical data were reported as percentages. Risk factors for liver fibrosis in patients with CHC were analysed using binary logistic regression. Only existing data were used for the analysis (and numbers are given where appropriate). There was no imputation procedure concerning missing data.
A predictive model for identifying significant fibrosis was developed using a training set, and then validated using a separate, independent validation set. Patients were randomised into a training set and a validation set (62%: 38% ratio). First, univariate analysis was performed to detect candidate variables from different clinical factors that could be incorporated into a new predictive model Data analysis was carried out using Statistica 13.3 (StatSoft, Kraków, Poland). Continuous variables were expressed as median (Q25-Q75) and compared using the Mann-Whitney U test; categorical data were reported as percentages. Risk factors for liver fibrosis in patients with CHC were analysed using binary logistic regression. Only existing data were used for the analysis (and numbers are given where appropriate). There was no imputation procedure concerning missing data.
The goodness of fit tests (AIC, BIC) were used to select the best model. In addition, to assess how well the data fits the model, the Hosmer-Lemeshow test was used. Variables with a P<0.01 in the univariate analysis were then included in a multivariate, stepwise, logistic regression analysis. Coefficients with P<0.10 in the multivariable analysis were then selected as components of a new equation for predicting significant fibrosis. First, univariate analysis was performed to detect candidate variables from different clinical factors that could be incorporated into a new predictive model Next, we tested the diagnostic accuracy of our new model derived from the training set using a validation set and determining the receiver operating characteristic (ROC) curve. The area under the ROC (AUROC) and its 95% confidence interval (CI) was calculated and the cut-off value determined using the Youden index. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and diagnostic accuracy (ACC) of our model was calculated. All P values were bilateral, and a P value of <0.05 was considered statistically significant. Finally, we compared the diagnostic performance of our predictive model (Pentra score) with the following markers or models of liver fibrosis: PTX3, GGT, GGT/PLT, HA, APRI index, FIB-4 score, Forns index [16, 27, 28] .
RESULTS
Patients' characteristics
The model was constructed using data obtained from 150 patients (training group) and validated using data from the remaining 92 patients (validation group). No significant difference was found in baseline characteristics between the training and validation group in any of the assessed variables or regarding liver biopsy. Patients' characteristics at the time of liver biopsy, including the detailed demographic and laboratory parameters of the subjects, are shown in TABLE 1.
Factors associated with significant liver fibrosis
In the univariate analysis, the following parameters were identified as positively related to When these 11 parameters were subsequently included in the multivariate analysis using forward stepwise procedures, age and PTX3 were found to be independent predictors of significant fibrosis. It should be added that the other two (GGT/PLT, and HA) variables have been included in the model to improve the fit of this model. (TABLE 3) . Viral load and genotype were available in 109 patients from the training group. Patients in whom genotype/viral load were available were not different from patients in whom these variables were not available in any of the analysed variables.
A novel model for the assessment of significant fibrosis
A predictive model was constructed by modeling the values of the independent variables and their coefficient of regression. As age (P < 0.001) and PTX3 (P = 0.009) were significant prognostic factors linked to the presence of significant fibrosis, and GGT/PLT (P = 0.08) and HA (P = 0.07) showed borderline statistical significance, we constructed a model, named the Pentra score, as follows:
Pentra score = 0.176*PTX3(ng/mL) + 0.522*HA(ng/mL) + 0.29*GGT(IU/L)/PLT(10 9 /L) + 0.14*age(years) -3.9346
Predictive value and diagnostic accuracy of the Pentra score
We assessed the utility of our model for stratification of groups with mild (F <2) and significant (F2) liver fibrosis. Using ROC analysis, an optimal cut-off point of 42.477 was determined for a diagnostic model based on the Pentra score: i.e., patients with a Pentra score of 42.477 had significant fibrosis, whereas those with a Pentra score lower then 42.477 had mild fibrosis. We then analysed the predictive and diagnostic accuracy of the The optimal cut-off value for each variable was adapted for the validation group. We then analysed the predictive and diagnostic accuracy of the Pentra score and the other seven methods in the validation group (Table 4B, FIGURE 1 ).
In the validation group, all subjects with a histopathologically confirmed diagnosis of significant fibrosis (53/53) were identified using the Pentra score, indicating a sensitivity of 100%. Moreover, of the 53 subjects identified by the Pentra score as having significant fibrosis (F2), the disease was confirmed histopathologically in 45 cases, giving a PPV of 83.3%.
DISCUSSION
Liver fibrosis is a serious, life-threatening disease with high morbidity and mortality that result from HCV infection. As mentioned above, liver biopsy, considered the "gold standard" for assessing liver fibrosis, has limitations in terms of invasiveness, cost, sampling variability, inter-observer variability, and the dynamic process of fibrosis. The invasiveness nature of liver biopsy makes it un-practical approach, especially for patients who require follow-up.
Compelling evidence has demonstrated that all stages of fibrosis are reversible if the injury is removed. Identifying HCV patients with fibrosis is of particular importance, as the choice of treatment regimen, including genotype-dependent treatment regimen (direct-acting antivirals-DAAs), depends on the severity of liver disease, and/or prior therapy. According to the EASL recommendations of 2018, there is a clear need for safe, effective, and reliable non-invasive assessment modalities to determine liver fibrosis and in order to manage it precisely in personalized medicine. Nowadays in CHC, noninvasive methods and not liver biopsy are considered as a reference standard [3] .
Some studies suggest that combining multiple non-invasive methods using special algorithms could enable more comprehensive first-line screening of liver fibrosis in patients with HCV compared to the use of single biomarkers or a liver biopsy alone [29, 30] . Indeed, patients who are only assessed via their aminotransferase levels could be misidentified as having severe fibrosis [31, 32] . While assessing a combination of serum fibrosis biomarkers might be more accurate [33, 34] , their routine use is somewhat limited by being non-specific to the liver and their high associated costs (i.e. for the patented tests). Despite this, serum fibrosis biomarkers are well validated, have good reproducibility, and can be carried out in outpatient clinics [35] [36] [37] , making them attractive for the non-invasive assessment of patients with CHC.
We developed a novel serum-based scoring system for the prediction of significant fibrosis in patients with CHC named the Pentra score. Its included: age, pentraxin 3, GGT / PLT, HA.
The Pentra score incorporates PTX3, an established marker for detecting clinically significant and advanced fibrosis in patients with CHC. We previously demonstrated that PTX3 levels increased with the progression of liver fibrosis stage in patients with HCV [26] . This is consistent with previous studies showing close associations between PTX3 levels, disease progression, and stages of liver fibrosis in patients with non-alcoholic steatohepatitis and/or alcoholic hepatitis, and chronic HCV [24, 38, 39] . In the present study, we also found that PTX3 was useful as a single diagnostic marker. However, the combined Pentra score appeared to be superior to using PTX3 alone for predicting significant fibrosis in CHC patients (i.e., AUROCs of 0.894 and 0.867 for the Pentra score in the training and validation groups, respectively, compared to 0.802 and 0.753 for PTX3). Moreover, the Pentra score had negative predictive value of 100%, and therefore, it could be used to identify patients without significant fibrosis in whom liver biopsy may not be required.
Previous studies have indicated that GGT levels are linked to the degree of liver fibrosis [40] [41] [42] [43] , and our multivariate analysis confirmed GGT levels were an independent predictor of significant fibrosis in patients with CHC. We also found platelet count was an independent predictor of significant fibrosis in CHC patients. Similar to our findings in CHC, both GGT levels and platelet count were previously shown to be independent predictors of significant fibrosis (F2 or more) in patients with chronic HBV infection [40] . Therefore, we incorporated both GGT and platelet count into our final model for predicting fibrosis.
HA is a glycosaminoglycan mainly synthesized by hepatic HSC and degraded by the liver sinusoidal cells. The increase of HA production and decrease of HA degradation contributed to serum HA increase in patients with liver fibrosis. Several studies tested the predictive performance of HA for liver fibrosis and suggested that a HA level less than 60 ng/ml had good accuracy to rule out patients with significant fibrosis or cirrhosis [44, 45] . Other studies showed that a higher cut point of HA level of 100-237 ng/mL could be used to identify the present of cirrhosis [46] . Rosenberg et al. [17, 47] first showed in 2004 that using a combination of biomarkers may improve the assessment of liver fibrosis compared to using a single factor alone. Their algorithm combining HA, the N-terminal propeptide of type III collagen, and the tissue inhibitor of matrix metalloproteinase 1 (as well as age) was predictive of significant fibrosis (F2 or more) in patients with liver disease with a sensitivity of 90% and a NPV of 92% [17] . Other studies showed that the combination of serum levels of HA, PIIINP and TGFβ is more reliable to evaluate the degree of liver fibrosis in comparison with each marker alone [48] .
The Pentra score had slightly higher AUROCs for predicting significant fibrosis (0.87) compared to those obtained by Rosenberg et al. (0.804); however, as we did not test the levels of N-terminal propeptide of type III collagen or tissue inhibitor of matrix metalloproteinase 1 in this study, it is difficult to directly compare our results. In addition to serum biomarkers, previous studies have shown age is an important risk factor in patients with CHC [49, 50] , and thus both the FIB-4 score and the Forns index include age in their calculations. We also found age to be an important predictor (P<0.001) associated with significant fibrosis, and therefore included this factor in the Pentra score.
A major strength of this study is that we validated our model in an independent group. The coefficient of determination of the Pentra score was 85.4%, indicating that the formula explained over 3/4 of the variation in fibrosis in the sample analysed. Moreover, the AUROC for the Pentra score was excellent (0.894). In addition, the Pentra score showed high sensitivity (100%) and specificity (73.5%), along with a high PPV (87.3%) and NPV (100%), supporting the efficacy of our model for identifying significant fibrosis in patients with CHC.
Despite this, the score validation in an independent sample of HCV-positive patients demonstrated slightly less favourable results compared to the training group, particularly in terms of specificity (62.5%). The lower specificity of the score in the validation group is likely to be associated with a lower number of patients with mild fibrosis compared to the training group (39 vs. 66) . Nonetheless, our model showed good sensitivity (100%), PPV (83.3%), and NPV (100%) in the validation group. Furthermore, our model comprising all significant independent variables (i.e., age, PTX3, GGT/PLT, HA) linked to liver fibrosis was more accurate (in terms of AUROC analyses) than some other existing non-invasive fibrosis indices we examined. Another advantage of the Pentra score over the currently available tests such as the APRI index, FIB-4 score, or Forns index is the absence of transaminases (ALT and AST) in its formula, which can lead to false positive results in acute hepatitis [31, 32] .
This study has some limitations. First, we used a relatively small sample size (n = 242), which should be increased in future to confirm our findings. Second, as we only included patients with CHC, the Pentra score requires further testing before it can be used for other types of chronic liver disease. Indeed, more validation studies that include cohorts of patients with other liver diseases (such as chronic hepatitis B or autoimmune hepatitis) would be of interest.
Third, our cohort of patients did not receive antiviral treatment, and therefore, whether the Pentra score will be of value for monitoring regression due to treatment requires further investigation.
In conclusion, the Pentra score is a new panel of biomarkers that can be used as a noninvasive method for the prediction of significant fibrosis in patients with CHC. The Pentra score can be applied to the clinic to assist physicians and patients when making the decision whether to embark on HCV treatment now, or to wait for more affordable treatment. This model can be applied to real-world clinical practice through existing medical records or as a broader web-based application. This is of great clinical importance in the new era of antiviral therapy where fibrosis regression becomes one of the major goals of treatment. Pentra score could be used for the initial evaluation of the treatment priority of newly diagnosed HCV infection.
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